Evidence map›Paper›PMID 42226728›Full record

ArticleBritish journal of haematology2026

Concurrent antiviral-immunochemotherapy strategy safely overcomes high hepatitis B viral load barrier in diffuse large B-cell lymphoma: A multicentre cohort study.

Yuxiao Zhao, Jingjing Guo, Xiran Wang, Lei Cao, Yi Xia, Haorui Shen, Ran Li, Ping Wu, Hongling Mi, Jing Zhang and 4 more

Abstract readMulticenter Study
In one paragraph

Article in British journal of haematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Yuxiao ZhaoDepartment of Hematology, Jiangsu Province Hospital, The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China.
Jingjing GuoDepartment of Geriatrics, The Second Hospital of Nanjing, Nanjing University of Chinese Medicine, Nanjing, People's Republic of China.
Xiran WangDepartment of Hematology, Jiangsu Province Hospital, The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China.
Lei CaoDepartment of Hematology, Jiangsu Province Hospital, The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China.
Yi XiaDepartment of Hematology, Jiangsu Province Hospital, The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China.ORCID https://orcid.org/0000-0002-2197-5865
Haorui ShenDepartment of Hematology, Jiangsu Province Hospital, The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China.
Ran LiDepartment of Hematology, Jiangsu Province Hospital, The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China.
Ping WuDepartment of Hematology, Sir Run Run Hospital Affiliated to Nanjing Medical University, Nanjing, Jiangsu, China.
Hongling MiDepartment of Hematology, Nanjing Pukou People's Hospital, Liangjiang Hospital, Southeast University, Nanjing, Jiangsu, People's Republic of China.
Jing ZhangDepartment of Hematology, Jiangsu Province Hospital, The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China.ORCID https://orcid.org/0000-0002-5302-9873
Jianyong LiDepartment of Hematology, Jiangsu Province Hospital, The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China.ORCID https://orcid.org/0000-0002-9931-4055
Hailing LiuDepartment of Hematology, Jiangsu Province Hospital, The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China.
Xiaoyan QuDepartment of Hematology, Jiangsu Province Hospital, The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China.
Lei FanDepartment of Hematology, Jiangsu Province Hospital, The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China.

Funding

Baiqiuen Medical Science Research Foundation 2023-YJ-119-J-024Beijing Xisike Clinical Oncology Research Foundation Y-SYBLD2022RWR-0013Jiangsu Province Hospital Clinical Capacity Enhancement Project JSPH-MC-2022-2Jiangsu Province Hospital High-Level Hospital Construction Project JBGS202404National Natural Science Foundation of China 82100211National Natural Science Foundation of China 82470186National Natural Science Foundation of China 82500242Natural Science Foundation of Jiangsu Province BK20232039Qilu Clinical Research Foundation of Nanjing Medical University 2024KF0252
6 · The paper itself

Abstract

Although antiviral prophylaxis is standard for lymphoma patients with chronic hepatitis B virus (HBV) infection to prevent HBV reactivation (HBVr), the optimal timing for high-risk patients (baseline HBV deoxyribonucleic acid (DNA) ≥4 log10 IU/mL) during immunochemotherapy remains unclear. A multicentre retrospective study analysed 112 chronic HBV patients among 1120 newly diagnosed diffuse large B-cell lymphoma (DLBCL) patients, stratified by baseline viral load (low: <10

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsAntiviral AgentsHepatitis B, ChronicHepatitis B virusLymphoma, Large B-Cell, DiffuseViral LoadAdultAgedAged, 80 and overDNA, ViralFemaleHumansMaleMiddle AgedRetrospective StudiesAntiviral AgentsDNA, Viralantiviral therapydiffuse large B‐cell lymphomaHBV DNAhepatitis B virusimmunosuppressive therapyreactivation

Identifiers

PMID42226728
PMCPMC13461973

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.